-
Mashup Score: 6The Current State of Treatment Implementation for Metastatic Hormone Sensitive Prostate Cancer in North America - 5 day(s) ago
prostate cancer, metastatic hormone sensitive prostate cancer (mHSPC), androgen deprivation therapy (ADT), apalutamide, enzalutamide, Current State of Treatment Implementation for Metastatic Hormone Sensitive Prostate Cancer, docetaxel, LATITUDE trial, STAMPEDE trial, GETUG-15 trial, CHAARTED trial, ENZAMET trial, Synchronous Low Volume mHSPC, Synchronous High Volume mHSPC, ARASENS trial, SWOG 1802 trial, TITAN trial, PEACE-1 trial, ARCHES trial, Primary Radiotherapy for synchronous, low volume mHSPC patients, Metachronous Low Volume mHSPC, HORRAD trial, GETUG-AFU15, Metachronous High Volume mHSPC.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 6The Current State of Treatment Implementation for Metastatic Hormone Sensitive Prostate Cancer in North America - 30 day(s) ago
prostate cancer, metastatic hormone sensitive prostate cancer (mHSPC), androgen deprivation therapy (ADT), apalutamide, enzalutamide, Current State of Treatment Implementation for Metastatic Hormone Sensitive Prostate Cancer, docetaxel, LATITUDE trial, STAMPEDE trial, GETUG-15 trial, CHAARTED trial, ENZAMET trial, Synchronous Low Volume mHSPC, Synchronous High Volume mHSPC, ARASENS trial, SWOG 1802 trial, TITAN trial, PEACE-1 trial, ARCHES trial, Primary Radiotherapy for synchronous, low volume mHSPC patients, Metachronous Low Volume mHSPC, HORRAD trial, GETUG-AFU15, Metachronous High Volume mHSPC.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 6The Current State of Treatment Implementation for Metastatic Hormone Sensitive Prostate Cancer in North America - 2 month(s) ago
prostate cancer, metastatic hormone sensitive prostate cancer (mHSPC), androgen deprivation therapy (ADT), apalutamide, enzalutamide, Current State of Treatment Implementation for Metastatic Hormone Sensitive Prostate Cancer, docetaxel, LATITUDE trial, STAMPEDE trial, GETUG-15 trial, CHAARTED trial, ENZAMET trial, Synchronous Low Volume mHSPC, Synchronous High Volume mHSPC, ARASENS trial, SWOG 1802 trial, TITAN trial, PEACE-1 trial, ARCHES trial, Primary Radiotherapy for synchronous, low volume mHSPC patients, Metachronous Low Volume mHSPC, HORRAD trial, GETUG-AFU15, Metachronous High Volume mHSPC.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 5The Current State of Treatment Implementation for Metastatic Hormone Sensitive Prostate Cancer in North America - 3 month(s) ago
prostate cancer, metastatic hormone sensitive prostate cancer (mHSPC), androgen deprivation therapy (ADT), apalutamide, enzalutamide, Current State of Treatment Implementation for Metastatic Hormone Sensitive Prostate Cancer, docetaxel, LATITUDE trial, STAMPEDE trial, GETUG-15 trial, CHAARTED trial, ENZAMET trial, Synchronous Low Volume mHSPC, Synchronous High Volume mHSPC, ARASENS trial, SWOG 1802 trial, TITAN trial, PEACE-1 trial, ARCHES trial, Primary Radiotherapy for synchronous, low volume mHSPC patients, Metachronous Low Volume mHSPC, HORRAD trial, GETUG-AFU15, Metachronous High Volume mHSPC.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 6The Current State of Treatment Implementation for Metastatic Hormone Sensitive Prostate Cancer in North America - 5 month(s) ago
prostate cancer, metastatic hormone sensitive prostate cancer (mHSPC), androgen deprivation therapy (ADT), apalutamide, enzalutamide, Current State of Treatment Implementation for Metastatic Hormone Sensitive Prostate Cancer, docetaxel, LATITUDE trial, STAMPEDE trial, GETUG-15 trial, CHAARTED trial, ENZAMET trial, Synchronous Low Volume mHSPC, Synchronous High Volume mHSPC, ARASENS trial, SWOG 1802 trial, TITAN trial, PEACE-1 trial, ARCHES trial, Primary Radiotherapy for synchronous, low volume mHSPC patients, Metachronous Low Volume mHSPC, HORRAD trial, GETUG-AFU15, Metachronous High Volume mHSPC.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 6The Current State of Treatment Implementation for Metastatic Hormone Sensitive Prostate Cancer in North America - 5 month(s) ago
prostate cancer, metastatic hormone sensitive prostate cancer (mHSPC), androgen deprivation therapy (ADT), apalutamide, enzalutamide, Current State of Treatment Implementation for Metastatic Hormone Sensitive Prostate Cancer, docetaxel, LATITUDE trial, STAMPEDE trial, GETUG-15 trial, CHAARTED trial, ENZAMET trial, Synchronous Low Volume mHSPC, Synchronous High Volume mHSPC, ARASENS trial, SWOG 1802 trial, TITAN trial, PEACE-1 trial, ARCHES trial, Primary Radiotherapy for synchronous, low volume mHSPC patients, Metachronous Low Volume mHSPC, HORRAD trial, GETUG-AFU15, Metachronous High Volume mHSPC.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 6The Current State of Treatment Implementation for Metastatic Hormone Sensitive Prostate Cancer in North America - 6 month(s) ago
prostate cancer, metastatic hormone sensitive prostate cancer (mHSPC), androgen deprivation therapy (ADT), apalutamide, enzalutamide, Current State of Treatment Implementation for Metastatic Hormone Sensitive Prostate Cancer, docetaxel, LATITUDE trial, STAMPEDE trial, GETUG-15 trial, CHAARTED trial, ENZAMET trial, Synchronous Low Volume mHSPC, Synchronous High Volume mHSPC, ARASENS trial, SWOG 1802 trial, TITAN trial, PEACE-1 trial, ARCHES trial, Primary Radiotherapy for synchronous, low volume mHSPC patients, Metachronous Low Volume mHSPC, HORRAD trial, GETUG-AFU15, Metachronous High Volume mHSPC.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
The current state of treatment implementation for metastatic hormone-sensitive #ProstateCancer in #NorthAmerica. #LibraryResource @zklaassen_md @GACancerCenter and @RKSayyid @UofT discuss on UroToday > https://t.co/VDtUiLis3m https://t.co/zNuUo8rc9H